Nitrofurantoin is an antimicrobial widely used in the treatment and prophylaxis of recurrent urinary tract infections. It carries a potential risk of pulmonary complications, that, while low (
Pulmonary arteriovenous malformations (PAVMs) are rare vascular anomalies that can lead to severe complications when ruptured. We report the case of a 65-year-old active smoker who presented to the emergency department with acute pleuritic chest […]
Oculopharyngeal muscular dystrophy (OPMD) is a rare neuromuscular disorder that may present with respiratory complications, yet it is seldom considered in this context. We report a 68-year-old institutionalized man, independent in daily activities, who presented […]
Se evaluaron el conocimiento y la percepción sobre los determinantes sociales de la salud respiratoria (DSSR) entre los socios de la SEPAR mediante encuesta online anónima. Respondieron 293 profesionales (4,8% de socios). Aunque el 98,6% […]
To assess the real-life efficacy and safety of varenicline in a hospital-based smoking cessation program. We conducted a longitudinal prospective study including 310 smokers treated with varenicline at our hospital’s Smoking Cessation Unit between 2011 […]
The sale, distribution, and indiscriminate use of new tobacco and nicotine products have multiplied. The most relevant products are: electronic cigarettes (ECs), heated tobacco (HT), and nicotine pouches (NPs). From the tobacco industry and its […]
Non-invasive brain stimulation (NIBS) is emerging as a promising treatment for nicotine dependence. Several systematic reviews discuss the effectiveness of repetitive transcranial magnetic stimulation (rTMS) as monotherapy for smoking cessation; however, its effectiveness in combination […]
Alpha-1 antitrypsin (AAT) deficiency is an underdiagnosed genetic disorder that predisposes individuals to the development of pulmonary emphysema and liver disease. This document establishes ten priorities for the optimal management of AAT deficiency (AATD) in […]
Immune checkpoint inhibitors associated interstitial lung diseases (ICI-ILD) affect approximately 2–5% of patients receiving immunotherapy and represent one of the most serious and potentially life-threatening immune-related adverse events. The pathogenesis remains incompletely elucidated; however, current […]
